About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
CECOG Academy
www.cecog.org
Pancreas Cancer Academy 2022
Breast Cancer Webinar
NSCLC 2022 Webinar
CECOG Immuno-Oncology Symposium
Pancreatic Cancer
Colon Cancer
Post ESMO Webinar
Post SABCS Webinar
Videos
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
Expert Discussion on PRODIGE 24 Data on FOLFIRINOX vs. Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
By
CECOG Academy
FEATURING
Gerald Prager
,
Julien Taieb
,
Harpreet Wasan
,
Joon Oh Park
By
CECOG Academy
FEATURING
Gerald Prager
,
Julien Taieb
,
Harpreet Wasan
,
Joon Oh Park
0 views
March 31, 2021
Comments
0
Login to view comments.
Click here to Login
Featured Video
09:36
Johnson & Johnson
Mechanisms of Resistance in Locally Advanced or Metastatic EGFR+ NSC…
Feat.
J. Heymach,
M. Das
Featured Video
06:14
Lilly Medical Affairs
CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC
Feat.
J. O’Shaughnessy
Pancreatic Cancer
31:05
CECOG Academy
Modern Treatment Approaches in mPDAC: Overview of 1L/2L Options and …
Feat.
G. Prager
23:51
CECOG Academy
2021 ASCO Paradigm Changing Updates on Pancreatic Ductal Adenocarcin…
Feat.
T. Golan
35:20
CECOG Academy
2021 ASCO Abstracts Review in PAD: Palliative Care, Neoadjuvant Trea…
Feat.
T. Golan,
G. Prager,
C. Yoo,
E. Van Cutsem
28:06
CECOG Academy
Molecular Testing for Treatment Stratification on PDAC Patients: Whe…
Feat.
C. Neuzillet,
P. Hammel,
M. Ikeda
30:57
CECOG Academy
PDAC Expert Panel Discussion: Differences in Clinical Practice, Turn…
Feat.
C. Neuzillet,
P. Hammel,
M. Ikeda
23:53
CECOG Academy
mPAC Oligometastatic Disease Expert Discussion: Eligibility for 2nd …
Feat.
T. Seufferlein,
M. Falconi,
K. Uesaka
30:28
CECOG Academy
Updates on mPAC: Is There a Target Group for Oligometastatic Disease…
Feat.
T. Seufferlein
31:35
CECOG Academy
Expert Discussion on Resectable/Borderline-Resectable PAC: Gemcitabi…
Feat.
G. Prager,
T. Macarulla,
E. Van Cutsem,
C. Cheng Ean
23:59
CECOG Academy
Neoadjuvant Treatment Concepts for Resectable/Borderline-Resectable …
Feat.
T. Macarulla
29:00
CECOG Academy
Expert Discussion on PRODIGE 24 Data on FOLFIRINOX vs. Gemcitabine a…
Feat.
G. Prager,
J. Taieb,
H. Wasan,
J. Oh Park
26:51
CECOG Academy
Adjuvant Treatment Options for PAC Patients: Who Should Receive FOLF…
Feat.
J. Taieb
